UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation

Grant

Date/time Interval

  • September 9, 2019 - September 8, 2024
  • Total Award Amount

  • 132000.00
  • Direct Costs

  • 101538.00
  • Sponsor Award Id

  • Contributor

  • Bal, Susan   Investigator  
  • Costa M.D., Ph.D., Luciano   Principal Investigator  
  • De Idiaquez Bakula, Lorena   Investigator  
  • Giri, Smith   Investigator  
  • Godby M.D., Kelly   Investigator  
  • Innis-Shelton M.D., Racquel   Investigator